Summary of COVID-19 FX06 studies

1. Guérin et al., FX06 to rescue SARS-CoV-2-induced acute respiratory distress syndrome: a randomized clinical trial

49 patient FX06 ICU RCT: 10% higher mortality (p=1).
RCT 49 patients with COVID-19-associated ARDS showing no significant effect of FX06 on vascular leakage or mortality.
Aug 2023, Critical Care, https://ccforum.biomedcentral.com/articles/10.1186/s13054-023-04616-1, https://c19p.org/guerin2